---
layout: default
title: Leflunomide
description: "Leflunomide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 2 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 96
evidence_level: L5
indication_count: 2
---

# Leflunomide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>2</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Leflunomide (ä¾†æ°Ÿç±³ç‰¹) - è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Leflunomide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Leflunomide ç‚ºå…ç–«èª¿ç¯€åŠ‘ï¼Œç›®å‰æ ¸å‡†ç”¨æ–¼é¡é¢¨æ¿•æ€§é—œç¯€ç‚èˆ‡ä¹¾ç™¬æ€§é—œç¯€ç‚ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°ç½•è¦‹éª¨éª¼ç™¼è‚²ç•°å¸¸ç—‡å€™ç¾¤æœ‰æ²»ç™‚æ½›åŠ›ï¼Œä½†ç¼ºä¹è‡¨åºŠè­‰æ“šï¼Œå±¬æ–¼ç´”é æ¸¬éšæ®µ (L5)ã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Leflunomide (ä¾†æ°Ÿç±³ç‰¹) |
| DrugBank ID | DB01097 |
| å°ç£å•†å“å | è‰¾ç‚å¯§ã€é›…åŠªéº»ã€å¸Œé—œç‚ç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | é¡é¢¨æ¿•æ€§é—œç¯€ç‚ã€ä¹¾ç™¬æ€§é—œç¯€ç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | rheumatoid arthritisã€brachydactyly-syndactyly syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 0.999 |
| è­‰æ“šç­‰ç´š | **L5** (åƒ…é æ¸¬) |
| è‡¨åºŠè©¦é©— | ç„¡ |
| PubMed æ–‡ç» | ç„¡ |

---


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. brachydactyly-syndactyly syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

### æ©Ÿè½‰æ¨è«–

1. **DHODH æŠ‘åˆ¶ä½œç”¨**ï¼šLeflunomide é€éæŠ‘åˆ¶äºŒæ°«ä¹³æ¸…é…¸è„«æ°«é…¶ (DHODH) æ¸›å°‘å˜§å•¶åˆæˆï¼Œé€²è€ŒæŠ‘åˆ¶æ·‹å·´ç´°èƒå¢æ®–ã€‚é€™ç¨®æŠ‘åˆ¶ç´°èƒå¢æ®–çš„æ©Ÿè½‰åœ¨æŸäº›ç™¼è‚²ç•°å¸¸ç–¾ç—…ä¸­å¯èƒ½æœ‰ç†è«–ä¸Šçš„æ‡‰ç”¨ã€‚

2. **æŠ—ç™¼ç‚èˆ‡å…ç–«èª¿ç¯€**ï¼šä½œç‚º DMARD (ç–¾ç—…ä¿®é£¾æŠ—é¢¨æ¿•è—¥)ï¼Œå…¶å…ç–«èª¿ç¯€ç‰¹æ€§å¯èƒ½å°æŸäº›å…·æœ‰ç™¼ç‚æˆåˆ†çš„éºå‚³æ€§ç–¾ç—…æœ‰è¼”åŠ©ä½œç”¨ã€‚

3. **çŸ¥è­˜åœ–è­œé€£çµ**ï¼šTxGNN å¯èƒ½è­˜åˆ¥åˆ° Leflunomide çš„ä½œç”¨æ¨™é¶èˆ‡éª¨éª¼ç™¼è‚²ç›¸é—œåŸºå› ç¶²çµ¡çš„é—œè¯ï¼Œä½†é€™éœ€è¦é€²ä¸€æ­¥é©—è­‰ã€‚

### é æ¸¬é™åˆ¶

- é æ¸¬çš„é©æ‡‰ç—‡ (çŸ­æŒ‡ä½µæŒ‡ç—‡å€™ç¾¤ã€çœ¼ç¼ºæ-æ ¹è–éª¨ç™¼è‚²ä¸å…¨ç—‡å€™ç¾¤) ç‚ºæ¥µç½•è¦‹çš„å…ˆå¤©æ€§ç™¼è‚²ç•°å¸¸
- é€™äº›ç–¾ç—…çš„ç—…ç†æ©Ÿè½‰èˆ‡ Leflunomide çš„ä½œç”¨æ©Ÿè½‰ç¼ºä¹ç›´æ¥é—œè¯
- å…ˆå¤©æ€§éª¨éª¼ç™¼è‚²ç•°å¸¸é€šå¸¸é›£ä»¥è—¥ç‰©æ²»ç™‚é€†è½‰

### è‡¨åºŠè©¦é©—

**ç„¡ç›¸é—œè‡¨åºŠè©¦é©—**

åœ¨ ClinicalTrials.gov åŠ ICTRP è³‡æ–™åº«ä¸­ï¼Œæœªç™¼ç¾ Leflunomide ç”¨æ–¼é æ¸¬é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ã€‚

### ç›¸é—œæ–‡ç»

**ç„¡ç›¸é—œ PubMed æ–‡ç»**

åœ¨ PubMed è³‡æ–™åº«ä¸­ï¼Œæœªæ‰¾åˆ° Leflunomide èˆ‡çŸ­æŒ‡ä½µæŒ‡ç—‡å€™ç¾¤æˆ–çœ¼ç¼ºæ-æ ¹è–éª¨ç™¼è‚²ä¸å…¨ç—‡å€™ç¾¤ç›¸é—œçš„æ–‡ç»ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. colobomatous microphthalmia-rhizomelic dysplasia syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.93%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

### è¨±å¯è­‰ç‹€æ…‹

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | æŒè­‰å•† | ç‹€æ…‹ | æ•ˆæœŸ |
|-----------|--------|------|--------|------|------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬023615è™Ÿ | è‰¾ç‚å¯§è†œè¡£éŒ 10æ¯«å…‹ | è†œè¡£éŒ  | è³½è«¾è² | æœ‰æ•ˆ | 2027/12/30 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027175è™Ÿ | å¸Œé—œç‚è†œè¡£éŒ 10æ¯«å…‹ | è†œè¡£éŒ  | è¥¿æµ·ç”ŸæŠ€ | æœ‰æ•ˆ | 2027/06/06 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027176è™Ÿ | å¸Œé—œç‚è†œè¡£éŒ 20æ¯«å…‹ | è†œè¡£éŒ  | è¥¿æµ·ç”ŸæŠ€ | æœ‰æ•ˆ | 2027/06/06 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027098è™Ÿ | å¸Œé—œç‚è†œè¡£éŒ 100æ¯«å…‹ | è†œè¡£éŒ  | è¥¿æµ·ç”ŸæŠ€ | æœ‰æ•ˆ | 2027/03/28 |
| è¡›ç½²è—¥è£½å­—ç¬¬045971è™Ÿ | ç¾æ™‚ é›…åŠªéº»éŒ 20æ¯«å…‹ | éŒ åŠ‘ | ç¾æ™‚åŒ–å­¸è£½è—¥ | æœ‰æ•ˆ | 2028/12/05 |
| è¡›ç½²è—¥è£½å­—ç¬¬048558è™Ÿ | ç¾æ™‚ é›…åŠªéº»éŒ 10æ¯«å…‹ | éŒ åŠ‘ | ç¾æ™‚åŒ–å­¸è£½è—¥ | æœ‰æ•ˆ | 2027/01/26 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027234è™Ÿ | è€ç¦è«¾é‚ | ç²‰åŠ‘ | æ¼¢æ—­ | æœ‰æ•ˆ | 2027/08/14 |

### æ ¸å‡†é©æ‡‰ç—‡

- æ²»ç™‚æˆäººé¡é¢¨æ¿•æ€§é—œç¯€ç‚ï¼Œæ¸›ç·©é¡é¢¨æ¿•ç—…ç¨‹å°é—œç¯€æ‰€é€ æˆä¹‹çµæ§‹æ€§æå®³ (DMARD)
- æ²»ç™‚å…·æ´»å‹•æ€§çš„æˆäººä¹¾ç™¬æ€§é—œç¯€ç‚

---

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨ (DDI)

#### åš´é‡ (Major) äº¤äº’ä½œç”¨

| ä½µç”¨è—¥ç‰© | å½±éŸ¿èªªæ˜ |
|---------|---------|
| é¡å›ºé†‡é¡ (Hydrocortisone, Prednisone, Dexamethasone, Betamethasone, Triamcinolone ç­‰) | å¢åŠ è‚æ¯’æ€§é¢¨éšª |
| Statins (Rosuvastatin, Simvastatin) | å¢åŠ è‚æ¯’æ€§èˆ‡è‚Œç—…è®Šé¢¨éšª |
| Acetylsalicylic acid | å¢åŠ å‡ºè¡€é¢¨éšª |
| Clarithromycin | è—¥ç‰©äº¤äº’ä½œç”¨å¢å¼· |
| Minocycline | å¢åŠ è‚æ¯’æ€§é¢¨éšª |
| Levofloxacin | å¢åŠ è‚æ¯’æ€§é¢¨éšª |
| Sulfasalazine | å¢åŠ è‚æ¯’æ€§é¢¨éšª |
| Ethanol | é¡¯è‘—å¢åŠ è‚æ¯’æ€§é¢¨éšª |
| Pioglitazone, Rosiglitazone, Troglitazone | å¢åŠ è‚æ¯’æ€§é¢¨éšª |
| Eltrombopag | å¢åŠ è‚æ¯’æ€§é¢¨éšª |
| Fostamatinib | å¢åŠ è‚æ¯’æ€§é¢¨éšª |

#### ä¸­åº¦ (Moderate) äº¤äº’ä½œç”¨

| ä½µç”¨è—¥ç‰© | å½±éŸ¿èªªæ˜ |
|---------|---------|
| Warfarin, Dicoumarol | å¢å¼·æŠ—å‡è¡€æ•ˆæœ |
| Metronidazole, Tinidazole | è—¥ç‰©ä»£è¬å½±éŸ¿ |
| ç£ºè„²é¡é™è¡€ç³–è—¥ (Glimepiride, Glipizide, Glyburide ç­‰) | è¡€ç³–æ§åˆ¶å½±éŸ¿ |
| æ´»æ€§ç¢³ | é™ä½ Leflunomide å¸æ”¶ |

### é‡è¦è­¦èª

1. **è‚æ¯’æ€§**ï¼šLeflunomide å…·æœ‰è‚æ¯’æ€§é¢¨éšªï¼Œéœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
2. **å…ç–«æŠ‘åˆ¶**ï¼šå¯èƒ½å¢åŠ æ„ŸæŸ“é¢¨éšª
3. **è‡´ç•¸èƒæ€§**ï¼š**çµ•å°ç¦ç”¨æ–¼å­•å©¦**ï¼Œè‚²é½¡å©¦å¥³éœ€æœ‰æ•ˆé¿å­•
4. **æ´—è„«ç¨‹åº**ï¼šåœè—¥å¾Œè—¥ç‰©ä»£è¬ç‰©åœ¨é«”å…§åœç•™æ™‚é–“é•·ï¼Œå¿…è¦æ™‚éœ€é€²è¡Œ cholestyramine æ´—è„«ç¨‹åº
5. **éª¨é«“æŠ‘åˆ¶**ï¼šå¯èƒ½å°è‡´ç™½è¡€çƒæ¸›å°‘ã€è¡€å°æ¿æ¸›å°‘

### ç‰¹æ®Šæ—ç¾¤

- **å­•å©¦**ï¼š**ç¦ç”¨** - Category X
- **å“ºä¹³å©¦å¥³**ï¼š**ç¦ç”¨**
- **è‚åŠŸèƒ½ä¸å…¨**ï¼šç¦ç”¨
- **è…åŠŸèƒ½ä¸å…¨**ï¼šç„¡éœ€èª¿æ•´åŠ‘é‡ï¼Œä½†éœ€è¬¹æ…ç›£æ¸¬
- **è€å¹´äºº**ï¼šéœ€è¬¹æ…ä½¿ç”¨ï¼Œç›£æ¸¬è‚è…åŠŸèƒ½

---

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šThe consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.
- å»ºè­°ï¼šPatients should be advised to avoid excessive alcohol use during leflunomide treatment.

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç´«éŒèŠ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç´«éŒèŠ±å¯èƒ½å½±éŸ¿å…ç–«èª¿ç¯€è—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šé¿å…ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é«˜è¡€å£“ (Hypertension)** ğŸŸ¡ Moderate
- Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.

**IMMUNE SUPPRESSION** ğŸŸ¢ Minor
- Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe imm...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver...

**Peripheral Nervous System Diseases** ğŸŸ¢ Minor
- Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide shou...

**Lung Diseases** ğŸŸ¢ Minor
- The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patient...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### è—¥å¸«è©•ä¼°

| è©•ä¼°é …ç›® | çµè«– |
|---------|------|
| é æ¸¬å¯ä¿¡åº¦ | ä½ - ç¼ºä¹æ”¯æŒè­‰æ“š |
| æ©Ÿè½‰åˆç†æ€§ | ä½ - ç†è«–é€£çµè–„å¼± |
| è‡¨åºŠå¯è¡Œæ€§ | æ¥µä½ - å…ˆå¤©æ€§ç–¾ç—…é›£ä»¥è—¥ç‰©æ²»ç™‚ |
| å»ºè­°å„ªå…ˆåº¦ | ä¸å»ºè­°å„ªå…ˆè¿½è¹¤ |

### å»ºè­°

1. **ä¸å»ºè­°è‡¨åºŠæ¢ç´¢**ï¼š
   - é æ¸¬çš„é©æ‡‰ç—‡ç‚ºå…ˆå¤©æ€§ç™¼è‚²ç•°å¸¸ï¼Œç—…ç†æ©Ÿè½‰èˆ‡è—¥ç‰©ä½œç”¨ä¸ç¬¦
   - Leflunomide å…·æœ‰é¡¯è‘—è‚æ¯’æ€§èˆ‡è‡´ç•¸èƒæ€§ï¼Œå°ç½•è¦‹ç–¾ç—…çš„é¢¨éšªæ•ˆç›Šæ¯”ä¸ä½³

2. **ç¾æœ‰é©æ‡‰ç—‡æé†’**ï¼š
   - Leflunomide æ˜¯é¡é¢¨æ¿•æ€§é—œç¯€ç‚çš„æœ‰æ•ˆ DMARD
   - ä½¿ç”¨æ™‚éœ€åš´æ ¼ç›£æ¸¬è‚åŠŸèƒ½èˆ‡è¡€çƒè¨ˆæ•¸
   - è‚²é½¡å©¦å¥³ä½¿ç”¨å‰å¿…é ˆç¢ºèªæœªæ‡·å­•ä¸¦ä½¿ç”¨æœ‰æ•ˆé¿å­•

3. **æŒçºŒç›£æ¸¬**ï¼š
   - é—œæ³¨ Leflunomide åœ¨å…¶ä»–å…ç–«ç›¸é—œç–¾ç—…çš„ç ”ç©¶é€²å±•

### è­‰æ“šç­‰ç´šèªªæ˜

**L5 (åƒ…é æ¸¬)**ï¼šæ­¤é æ¸¬åƒ…åŸºæ–¼ TxGNN çŸ¥è­˜åœ–è­œåˆ†æï¼Œç¼ºä¹ä»»ä½•è‡¨åºŠè©¦é©—æˆ–æ–‡ç»æ”¯æŒã€‚è€ƒé‡è—¥ç‰©çš„å®‰å…¨æ€§ç‰¹æ€§èˆ‡é æ¸¬é©æ‡‰ç—‡çš„æ€§è³ªï¼Œä¸å»ºè­°é€²ä¸€æ­¥æ¢ç´¢ã€‚

---

*æœ¬ç­†è¨˜ç”± TxGNN è€è—¥æ–°ç”¨é æ¸¬ç³»çµ±ç”Ÿæˆï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*

*ç”Ÿæˆæ—¥æœŸï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Sodium Carbonate]({{ "/drugs/sodium_carbonate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Amorolfine]({{ "/drugs/amorolfine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cobicistat]({{ "/drugs/cobicistat/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Vigabatrin]({{ "/drugs/vigabatrin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Aluminum Chloride]({{ "/drugs/aluminum_chloride/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Leflunomideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/leflunomide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_leflunomide,
  title = {Leflunomideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/leflunomide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
